SKU: G61RHA20
SAADAVUS: Varud madalaima väärtusega turul
TARNIMINE: Sarnased päevased kaubatellimused varem kui 14
H00SIZE: 20 eksamit/komplekt SPECIFICITY: 98,90%
Sorteeri
Immunokromatograafia kiire kontroll
Kirjeldus
Külgliikumise immunokromatograafiline test, mis võttis kasutusele kaksikvärvisüsteemi.
SARS-CoV-2 antigeeni kvalitatiivseks tuvastamiseks ninaneelu tampooniproovist.
Kontroll sisaldab kolloidkullaga konjugaatpadja ja membraaniriba, mis on eelnevalt kaetud kontrolljälgedel (T) olevate SARS-CoV-2 antigeeni spetsiifiliste antikehadega.
Kontrolljälgedel tundub visuaalselt must riba (antikeha-antigeeni-antikeha kuldkonjugaat on keeruline) (T) Kui proovis on SARS-CoV-2 antigeen.
Juhtimisliin (C) näitab, et kontroll viiakse läbi nõuetekohaselt.
Hinnatud paneeliprooviga (n = 75) PCR järgi
Tundlikkus: 90,2 %
Spetsiifilisus: 100 %
VITROS SARS CoV2 antigeeni CLIA juhtimine, mis põhineb peamiselt Ortho Medicali kontrollil
Diagnostika
1. VITROS SARS CoV2 antigeeni test on kemoluminestseeruv immuunanalüüs, mis on ette nähtud
SARS-CoV-2 nukleokapsiidi antigeenide kvalitatiivseks tuvastamiseks nina-neelu (NP) proovides inimestelt, kellel
kahtlustatakse COVID-19 ühe kuni viie päeva jooksul pärast sümptomite ilmnemist. või
asümptomaatilistelt inimestelt kogutud turba keskel olevad isendid .
2. Analüüs tuleks läbi viia VITROS 3600 immunodiagnostikasüsteemis või VITROS 5600 / VITROS XT 7600
sisseehitatud süsteemis firmalt Ortho.
Funktsioonid
COVID-19, ninaneelu tampoonid
Kalibreerimisviis
Kvalitatiivne
VITROS SARS CoV2 antigeeni test – protseduurilised sammud: –
1. etapp: Ninaneelu tampooniproovide valik:
1. Hankige ninaneelu tampooniproov, sisestades steriilse tampooni ninasõõrmesse.
2. Lükake steriilset tampooni, kuni turbinaadi laval tekib takistus.
3. Pöörake steriilset tampooni mitu korda nina -neelu seina poole ja minge
10 sekundiks sellesse kohta, et tampooni otsik küllastuks.
4. Võtke tampoon kiiresti ninasõõrmelt ära.
5. Asetage tampooniproov viirustranspordi puhvertuubi ja sulgege toru tihedalt.
6. Viige tampoonimuster VTM -is jahedas ahelas laborisse.
7. Mustrit saab toatemperatuuril (alla 30 ° C) salvestada kuni 24 tunniks
mustrivalikus või temperatuuril 2–8 ° C koguni 48 tundi alates mustrivaliku ajast.
2. etapp: mustri ettevalmistamine testimiseks:
1. Mustri ettevalmistamine peab toimuma labori BSL-2 astmekapis.
2. Kombineerige tampooniproov kenasti VTM-torusse (keeristage umbes 3-5 sekundit).
3. Lülitage 100 μL VITROS SARS-CoV-2 antigeeni ekstraheerimispuhver otse märgistatud uue mustriga tuubi.
4. Lisage ülaltoodud katsutisse 400 μL viiruse mustrit (et hoolitseda 1: nelja suhtega ekstraheerimispuhvri
ja mustri vahel).
COVID-19 Ag Rapid Test, Cs |
|||
R0182C | CTK Biotech | 20 | EUR 1.25 |
COVID-19 Ag Self-Test. Cs |
|||
R0182CST | CTK Biotech | 1,2,5 | EUR 1.65 |
COVID-19 Ag Rapid Test External Control Kit |
|||
C0182 | CTK Biotech | each | EUR 520 |
Flu A & Flu B & Covid-19 Ag Rapid Test |
|||
GF101A3 | Shenzhen Lvshiyuan Biotechnology | 25 Test/kit | Ask for price |
Panbio COVID-19 AG RAPID T Device 25T NP |
|||
41FK10 | Abbott | 25 Tests/Kit | EUR 220 |
Panbio COVID-19 AG RAPID T DEVICE 25T NS |
|||
41FK11 | Abbott | 25 Tests/Kit | EUR 123.75 |
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
COVID-19 + Influenza A. B Ag Rapid Test, Cs |
|||
R0188C | CTK Biotech | 1fi | Ask for price |
COVID-19 Ag Detection Kit (Colloidal Gold Immunochromatography) |
|||
MBS398097-20Tests | MyBiosource | 20Tests | EUR 325 |
Truenat™ COVID-19 |
|||
601430005 | Molbio Diagnostics Private Limited | 5T | EUR 60 |
Truenat™ COVID-19 |
|||
601430020 | Molbio Diagnostics Private Limited | 20T | EUR 240 |
Truenat™ COVID-19 |
|||
601430050 | Molbio Diagnostics Private Limited | 50T | EUR 600 |
COVID-19 variant pack |
|||
SB072 | Smartox Biotechnology | 0.5 | EUR 2325.81 |
Description: SARS-CoV-2 Spike (S) glycoprotein:Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein in a class I fusion protein that allows the virus to enter host cells.Variants package available:Some proteins of Sars-CoV-2 are identified as leading targets for COVID-19 therapies. SB-PEPTIDE offers a special pack pre-made peptide libraries of Spike protein including peptides from COVID-19 variants: UK COVID-19 variant B.1.1.7, South Africa COVID-19 variant B.1.351, Brazil COVID-19 variant B.1.1.248. SB-PEPTIDE offers additional plate containing only peptides with Spike S protein mutation of COVID-19 B.1.1.7, B.1.3.5.1 and B.1.1.248 (cited below).Variants package and Spike (S) glycoprotein peptide library can be used for T-cell assays, immune monitoring, antigen specific T-cell stimulation, T-cell expansion and cellular immune response. |
COVID-19 Spike Antigen |
|||
30-2018 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Spike recombinant antigen |
COVID-19 Spike Antigen |
|||
30-2019 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Spike recombinant antigen |
Moderna COVID-19 Vaccine |
|||
H7N7-319 | Creative BioMart | 1 vial | EUR 798.4 |
Description: Protein |
SARS & COVID-19 coronavirus |
|||
3862 | Virostat | each | EUR 330 |
Description: nucleoprotein |
SARS & COVID-19 coronavirus |
|||
3863 | Virostat | each | EUR 330 |
Description: nucleoprotein |
SARS & COVID-19 coronavirus |
|||
3864 | Virostat | each | EUR 330 |
Description: nucleoprotein |
COVID-19 Negative Control |
|||
MBS412771-05mL | MyBiosource | 0.5mL | EUR 100 |
COVID-19 Negative Control |
|||
MBS412771-5x05mL | MyBiosource | 5x0.5mL | EUR 305 |
COVID-19 Nucleocapsid protein |
|||
30-2005 | Fitzgerald | 1 mg | EUR 700 |
Description: COVID-19 Nucleocapsid protein recombinant antigen |
COVID-19 Nucleocapsid protein |
|||
30-2006 | Fitzgerald | 1 mg | EUR 700 |
Description: COVID-19 Nucleocapsid protein recombinant Antigen |